Peps
The short answer
BPC-157 is not an FDA-approved drug for any condition. It has not completed the controlled human trials that approval requires. Products sold as "research use only" are not medicines, and that label does not mean they have been checked for human safety.
What the FDA has said
The FDA lists BPC-157 among bulk drug substances for compounding that may present significant safety risks. The agency says compounded BPC-157 may carry a risk of immune reactions for some routes of administration, raises concerns about peptide-related impurities and characterizing the active ingredient, and states that it has no or only limited safety information for the proposed routes. As a result, the FDA says it lacks enough information to know whether BPC-157 would cause harm in people.
That page was checked for this guide on October 5, 2026. Regulatory status can change, so the FDA page is the place to confirm the current position.
What the research actually covers
Most BPC-157 healing research is in rats. A 2003 study, for example, reported better tendon strength, function and tissue organization after a surgically cut Achilles tendon, and a 2010 rat study reported better healing of a damaged knee ligament. These are useful early findings, but rat injury models often fail to predict results in people.
The human evidence is very thin. A 2025 pilot report monitored two previously exposed adults for three days and found no measurable changes in the organ-function tests used. That is far too small and short to show safety, and it did not test whether BPC-157 helps healing.
Source: Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. ↗
Source: Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. ↗
How to read claims you see online
When a website, video or seller describes BPC-157 as proven, ask which study they mean and who was studied. If the answer is rats or cells, the claim has gone further than the evidence. Our BPC-157 profile lists each study with its population, design and limits.
Source: Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. ↗
Continue with the original research
Study examples are based on selected publication abstracts and the explicitly described source documents. This is not a systematic review or an individualized treatment guide. Editorial scope and methods.